Clinical Trial Update: Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating verteporfin photodynamic therapy in combination with ranibizumab for subfoveal choroidal neovascularization due to age-related macu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Ranibizumab (ranibizumab)
• Verteporfin (verteporfin)

Snippet

Sponsor: Novartis | Conditions: Macular Degeneration, Choroidal Neovascularization | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2011-02-04